BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Novo Nordisk (NJ) (NVO) Receives Subpoena in the U.S.


2/16/2011 6:36:44 AM

BAGSVAERD, DENMARK--(Marketwire - 02/16/11) - The office of the US Attorney for the District of Massachusetts has served Novo Nordisk with a subpoena calling for the production of documents regarding potential criminal offences relating to the company's marketing and promotion practices for the following products: NovoLog®, Levemir®, and Victoza®. Novo Nordisk will cooperate with the US Attorney in this investigation.

At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information.

Read the full announcement in PDF format: http://hugin.info/2013/R/1489420/424931.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

Contact:

Further information: Media: Rachel Curtis Graversen Tel: (+45) 4442 7603 Email Contact In North America: Ken Inchausti Tel: (+1) 609 786 8316 Email Contact Investors: Klaus Bulow Davidsen Tel: (+45) 4442 3176 Email Contact Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 Email Contact Jannick Lindegaard Tel: (+45) 4442 4765 Email Contact In North America Hans Rommer Tel: (+1) 609 919 7937 Email Contact

Read at BioSpace.com
Read at Reuters
Read at Bloomberg
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->